AstraZeneca Pharma India Wraps Up FY26 With ₹5.79 Billion Revenue, Strong Profits, And A Generous ₹36 Dividend

AstraZeneca Pharma India Ltd reported revenue from operations of ₹5.79 billion and a profit after tax of ₹448.8 million for the March quarter, while recommending a dividend of ₹36 per equity share for FY2025-26. The results reflect the pharmaceutical major's strong commercial execution in India, driven by its oncology, cardiovascular, and respiratory therapy portfolios that continue to gain traction among healthcare providers across the country.

AstraZeneca Pharma India has delivered a March quarter that combines healthy revenue growth with solid profitability and a notably generous dividend recommendation. The ₹36 per share payout for FY26 stands out as one of the more substantial dividend announcements in the listed pharmaceutical space, underscoring the company's robust cash generation and its commitment to returning meaningful value to shareholders.

Quarterly Revenue And Commercial Momentum

Revenue from operations at ₹5.79 billion for the March quarter reflects AstraZeneca Pharma India's strong market presence across its core therapy areas. The company's focus on innovative medicines in oncology, diabetes, cardiovascular diseases, and respiratory conditions positions it favourably in a healthcare market where chronic disease management is driving sustained prescription growth and increasing demand for differentiated pharmaceutical solutions.

Profit After Tax And Financial Health Indicators

A profit after tax of ₹448.8 million for the March quarter is a strong bottomline outcome that reflects both the premium pricing power of AstraZeneca's innovative drug portfolio and the company's ability to manage operating expenses effectively. The PAT performance also provides a solid foundation for the generous dividend recommendation, confirming that the payout is well-supported by the company's underlying earnings and cash flow generation.

Dividend Of ₹36 Per Share — A Standout Shareholder Reward

The recommendation of a ₹36 per equity share dividend for FY2025-26 is a compelling signal of financial confidence from the AstraZeneca Pharma India board. For investors in the pharmaceutical sector, this level of dividend payout is particularly noteworthy and adds significantly to the total return profile of holding the stock over the long term.

Key Highlights

1. Revenue from operations reported at ₹5.79 billion for the March quarter
2. Profit after tax came in at ₹448.8 million for Q4 FY26
3. Dividend of ₹36 per equity share recommended for FY2025-26
4. Strong performance across oncology, cardiovascular, and respiratory therapy segments
5. Generous dividend reflects robust cash generation and shareholder-friendly capital allocation

Sources: AstraZeneca Pharma India Ltd Corporate Announcement, BSE/NSE Exchange Filings